Two years after AbbVie’s loss of market exclusivity for Humira, those “How it Started and How it’s Going” memes are looking ...

He emphasized the consistent outperformance of the ex-Humira platform, which grew over 18% annually and accelerated to 22% growth in Q4. The company projects mid-single-digit revenue growth in 2025, ...

AbbVie's strong earnings and growth projections make it a solid buy for 2025, with no major patent expirations until 2030.

AbbVie saw fourth-quarter sales handily beat Wall Street's projections as gains from its newer anti-inflammatory drugs helped offset declines from Humira, once its best performing asset. The drugmaker ...

By Christy Santhosh and Puyaan Singh (Reuters) -AbbVie forecast 2025 profit above estimates on Friday, as strong sales of its ...